ArticleBiochemical genetics2026
EGCG Alleviates Lipopolysaccharide-Induced Septic Shock by Inhibiting NET-Mediated ROS Production by Regulating CXCL2 Expression.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New Exploration of Therapeutic Targets for Radiation Pneumonitis: Comparative Analysis of Molecular Pathways in Radiation-Induced and LPS-Induced Pneumonitis.International journal of medical sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In septic shock, neutrophil extracellular traps (NETs)-mediated reactive oxygen species (ROS) drive inflammation and organ failure, with reducing excessive NETs emerging as a therapeutic strategy. This study aimed to investigate whether chemokine (C-X-C motif) ligand 2 (CXCL2), previously linked to NET formation in acute lung injury (ALI), serves as a target for septic shock and whether epigallocatechin-3-gallate (EGCG) exerts protective effects via CXCL2. Through bioinformatics analysis and RT-qPCR, CXCL2 was found highly expressed in serum from septic shock patients and lipopolysaccharide (LPS)-induced septic rats, correlating with increased NETs (MPO-DNA, dsDNA, and H3Cit) and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). In vitro, knocking down CXCL2 in human neutrophils significantly inhibited phorbol myristate acetate (PMA)-induced NETs formation and ROS production. In septic rats, treatment with EGCG reduced the levels of CXCL2 in serum and bronchoalveolar lavage fluid (BALF), suppressed markers of NETs in serum, BALF, and lung tissue, and alleviated lung inflammation. In vitro, EGCG significantly inhibited PMA-induced NETs formation and ROS production. Mechanistically, EGCG inhibited NETs and ROS by downregulating CXCL2, with these effects reversed by the overexpression of CXCL2. These findings confirm that CXCL2 promotes NET-mediated ROS production in septic shock, and EGCG alleviates injury by targeting CXCL2, highlighting CXCL2 as a potential therapeutic target and EGCG as a promising agent for septic shock treatment.
Indexed as
Identifiers
40670867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.